214 related articles for article (PubMed ID: 22639165)
1. Animal models for vaccine therapy.
Chung DS; Kim CH; Hong YK
Adv Exp Med Biol; 2012; 746():143-50. PubMed ID: 22639165
[TBL] [Abstract][Full Text] [Related]
2. Cell-Based Immunotherapy of Gliomas.
Everson RG; Antonios JP; Liau LM
Prog Neurol Surg; 2018; 32():90-100. PubMed ID: 29990977
[TBL] [Abstract][Full Text] [Related]
3. Peptide vaccine therapy for childhood gliomas.
Pollack IF; Jakacki RI; Butterfield LH; Okada H
Neurosurgery; 2013 Aug; 60 Suppl 1():113-9. PubMed ID: 23839362
[No Abstract] [Full Text] [Related]
4. [Peptide vaccination therapy for malignant glioma].
Yamanaka R; Itoh K
Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
[TBL] [Abstract][Full Text] [Related]
5. The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.
Maxwell R; Luksik AS; Garzon-Muvdi T; Lim M
Curr Neurol Neurosci Rep; 2017 Jun; 17(6):50. PubMed ID: 28488122
[TBL] [Abstract][Full Text] [Related]
6. Immunogene therapy as a treatment for malignant brain tumors in young mice.
Glick RP; Lichtor T; Lin H; Tarlock K; Cohen EP
J Neurosurg; 2006 Jul; 105(1 Suppl):65-70. PubMed ID: 16871873
[TBL] [Abstract][Full Text] [Related]
7. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
[TBL] [Abstract][Full Text] [Related]
8. Galectin-1 and immunotherapy for brain cancer.
Verschuere T; De Vleeschouwer S; Lefranc F; Kiss R; Van Gool SW
Expert Rev Neurother; 2011 Apr; 11(4):533-43. PubMed ID: 21469926
[TBL] [Abstract][Full Text] [Related]
9. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.
Fenstermaker RA; Ciesielski MJ; Qiu J; Yang N; Frank CL; Lee KP; Mechtler LR; Belal A; Ahluwalia MS; Hutson AD
Cancer Immunol Immunother; 2016 Nov; 65(11):1339-1352. PubMed ID: 27576783
[TBL] [Abstract][Full Text] [Related]
10. Vaccine Therapy of High-Grade Gliomas.
Ishikawa E; Muragaki Y; Yamamoto T; Ohno T; Matsumura A
Prog Neurol Surg; 2018; 32():101-111. PubMed ID: 29990978
[TBL] [Abstract][Full Text] [Related]
11. Peptide vaccine.
Izumoto S
Adv Exp Med Biol; 2012; 746():166-77. PubMed ID: 22639167
[TBL] [Abstract][Full Text] [Related]
12. [CTL precursor-oriented peptide vaccine therapy for malignant glioma].
Yajima N; Yamanaka R; Tanaka R; Shigemori M; Mine T; Itoh K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():582-7. PubMed ID: 16201585
[No Abstract] [Full Text] [Related]
13. Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.
Hofman FM; Stathopoulos A; Kruse CA; Chen TC; Schijns VE
Anticancer Agents Med Chem; 2010 Jul; 10(6):462-70. PubMed ID: 20879986
[TBL] [Abstract][Full Text] [Related]
14. Peptide-based immunotherapeutic approaches to glioma: a review.
Yamanaka R; Itoh K
Expert Opin Biol Ther; 2007 May; 7(5):645-9. PubMed ID: 17477802
[TBL] [Abstract][Full Text] [Related]
15. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.
Yang L; Ng KY; Lillehei KO
Cancer Control; 2003; 10(2):138-47. PubMed ID: 12712008
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell vaccines and immunity in glioma patients.
Wheeler CJ; Black KL
Front Biosci; 2005 Sep; 10():2861-81. PubMed ID: 15970541
[TBL] [Abstract][Full Text] [Related]
17. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
18. Monitoring immune responses after glioma vaccine immunotherapy.
Jian B; Yang I; Parsa AT
Neurosurg Clin N Am; 2010 Jan; 21(1):195-9. PubMed ID: 19944978
[TBL] [Abstract][Full Text] [Related]
19. Glioma antigen.
Toda M
Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-based active specific immunotherapy for malignant glioma.
Parajuli P; Mathupala S; Mittal S; Sloan AE
Expert Opin Biol Ther; 2007 Apr; 7(4):439-48. PubMed ID: 17373896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
